β
Outcome Measurepharmacokinetics

T max

Time to Maximum Plasma Concentration

2 Papers in Blossom

Outcome Data Across Studies

Reported results for T max across 2 studies with quantitative data.

Outcome data across 4 study arm–timepoint observations
SD
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study
2025Secondary
5-MeO-DMT 12 mg(experimental)0—20.0——
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression
2026Secondary
Biphasic(experimental)51018.4——
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression
2026Secondary
Biphasic(experimental)151021.1——
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression
2026Secondary
Biphasic(experimental)60103.8——

Papers Using T max

Paywallindividual

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression

In a 12‑week, open‑label phase 2a trial of a single 10 mg intranasal dose of 5‑methoxy‑N,N‑dimethyltryptamine (BPL‑003) in 12 patients with treatment‑resistant major depressive disorder, the drug was generally well tolerated with mostly mild–moderate adverse events and rapid discharge readiness (median ~98 minutes). A rapid and sustained mean MADRS reduction of 12–13 points was observed across Days 2–85, with most participants meeting response criteria and several achieving remission, supporting further evaluation in larger controlled trials.

Published
Journal
Journal of Psychopharmacology
Authors
Roberts, C., Seynaeve, M., Ermakova, A. O., Dunbar, F., Wells, H., Puri, A., Bird, C., Rucker, J. J.
Paywallindividual

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study

This Phase I clinical trial (n=36) of sublingual 5-MeO-DMT (6-12 mg weekly doses over four weeks) in adults with moderate to high anxiety/depression demonstrated good safety and tolerability with no significant adverse events, rapid absorption with peak plasma concentrations at 20 minutes, dose-dependent neurophysiological modulation without full psychedelic effects, and maintenance of normal cognitive and behavioral function.

Published
Journal
Neuropsychopharmacology
Authors
Beatriz, M., Millón, B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D. E., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L., Garcés, M. A., Diez, P., Albarracín, S. G., Bruno, M. A.

Quick Facts

Full Name
Time to Maximum Plasma Concentration
Domain
pharmacokinetics
Papers Indexed
2
Unit
hours
All Measures